Johnson & Johnson Starts Second Global Phase III Clinical Trial of Janssen COVID-19 Vaccine

News
Article

A second global Phase III clinical trial investigating the safety and efficacy of a two-dose regimen of JNJ-78436735 has been initiated by Johnson & Johnson.

A second global Phase III clinical trial investigating the safety and efficacy of a two-dose regimen of JNJ-78436735, Janssen’s investigational vaccine candidate for the prevention of COVID-19, has been initiated by Johnson & Johnson.

According to a Nov. 15, 2020 press release, the ENSEMBLE 2 clinical trial will complement the ENSEMBLE trial, which is still enrolling and vaccinating study participants. The ENSEMBLE 2 trial is a randomized, double-blind, placebo-controlled clinical trial that has been designed to assess whether a two-dose vaccine regimen is safe and effective in adults versus placebo.

The company aims to enroll participants in Belgium, Colombia, France, Germany, the Philippines, South Africa, Spain, the United Kingdom, and the United States in its ENSEMBLE 2 trial. Additionally, the ENSEMBLE 2 trial is being conducted in collaboration with the UK National Institute for Health Research.

Both Phase III clinical trials, assessing a single-dose regimen and two-dose regimen, follow positive interim study results from an ongoing Phase I/IIa clinical study, which is investigating the safety profile and immunogenicity of both a single-dose and two dose vaccination.

Source: Johnson & Johnson

Recent Videos
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.
Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.
Mike Baird from Schlafender Haser discusses industry trends from 2024 and those expected to have an impact in 2025 from the perspective of a software developer.
Preeya Beczek from Beczek.COM gives her thoughts on the areas to watch with the new US administration and how Europe might be finalizing preparations for previous legislative changes
Related Content